News: POLARIX meets Phase III Primary Goals

Roche has just reported that their Polivy combination therapy has reached its primary endpoints during the Phase III POLARIX clinical trial. The drug is being tested in combination with chemotherapy to treat diffuse large B-cell lymphoma (DLBCL.)


Polivy is an anti-CD79b antibody-drug-conjugate (ADC) which works by attaching itself to B cells and delivering an anti-cancer treatment. This is believed to reduce the negative impact of treatment on normal, healthy cells.


The POLARIX trial was a global, randomized placebo-controlled trial testing the efficacy, safety, and tolerability as well as the pharmacokinetics of Polivy in addition to traditional chemotherapy treatments.


The standard of care regimen involved MabThera/Rituxan, cyclophosphamide, doxurubicin, vincristine and prednisone. The trial demonstrated a significant improvement in the rates of progression-free survival for patients taking the Polivy treatment arm -- meeting the trial’s primary goal.


The safety profile is still in line with previous trial stages.


Notably, Polivy in addition to Chemo. Is the first treatment in around twenty years to improve the outcomes in the previously untreated, aggressive form of B cell lymphoma. Under a normal course of treatment, people with this kind of cancer face a 40% relapse rate after their initial treatment, according to the Roche chief medical officer.


Soon, the data from this trial will be submitted to health authorities across the world. Though, the drug is already approved for use alongside the aforementioned combination therapies in many countries including across the EU and in the US.


Want to Learn More?

In addition to keeping you up to date on all things clinical trials, we also act as a digital CRO with a specific focus on patient recruitment and retention. We believe that patient recruitment and study startup (especially study design and study material) are heavily intertwined. After all, study design can make or break clinical trials, and the patient-perspective should be considered when designing studies to ensure that patient targets are met not only on time, but also on budget.


For Citruslabs, patient recruitment starts with study design and ends with trial completion. We recruit patients through our network of health apps, which enables you to connect with thousands of patients in real time. The best part: these patients are already educated and prepared for the clinical trial process.


If you’d like to hear more about what we do, go here to read about what sets us apart, or here to read what our patients have to say about us.